CLNN

Clene Inc. (CLNN) - Q1 2026 10-Q Summary

Business Context and Reporting Period

Company: Clene Inc.
Reporting Period: Quarter ended March 31, 2026
Business Model: Clinical-stage pharmaceutical company developing clean-surfaced nanotechnology therapeutics for central nervous system disorders (ALS, MS, Parkinson's). Revenue is currently derived from dietary supplements sold via subsidiary dOrbital, Inc. and related party 4Life Research LLC.
Status: Non-accelerated filer, Smaller Reporting Company.

Key Financial Metrics

Note: All figures in thousands except per share data.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue dropped 81% to $15,000, driven by a 98% decrease in product revenue ($1,000 vs. $64,000) and an 18% decrease in royalty revenue ($14,000 vs. $17,000) from related party 4Life.
• Net Loss Expansion: Net loss increased 977% to $8.1 million. This was primarily driven by a $4.6 million non-cash "loss on initial issuance of equity" from a January 2026 public offering, a $1.1 million loss from changes in fair value of warrant liabilities, and increased interest expense.
• Operating Expense Reduction: Total operating expenses decreased 50% to $2.1 million. Research and Development (R&D) expenses fell 78% to $329,000, and General and Administrative (G&A) expenses fell 34% to $1.7 million, reflecting cost-saving initiatives and reduced clinical trial spending.
• Financing Activity: The company raised $6.0 million in gross proceeds from a registered direct offering in January 2026. Subsequent to the quarter end (May 2026), an additional $7.0 million was raised.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for the next 12 months without additional financing. Cash burn remains high relative to cash on hand.
• Regulatory Milestone: Following a Type C meeting with the FDA, the company intends to submit a New Drug Application (NDA) for CNM-Au8 for ALS under the accelerated approval pathway in Q3 2026. The FDA indicated the proposed data may support this pathway.
• Debt Covenants: The company must maintain unrestricted cash of at least $2.0 million to avoid acceleration of its Senior Secured Convertible Promissory Notes (SSCP Notes). As of March 31, 2026, cash was $5.9 million, meeting this covenant.
• Unusual Items:
  • Equity Issuance Loss: A $4.6 million loss was recognized because the fair value of warrants issued in the January 2026 offering exceeded the proceeds received.
  • Warrant Liability Volatility: Significant fluctuations in fair value of common stock warrant liabilities and derivative liabilities impacted the bottom line.
• Internal Controls: The company disclosed material weaknesses in internal control over financial reporting, specifically regarding the control environment, manual journal entries, and IT general controls.

Investor Verification Checklist

• Liquidity Runway: Verify if the $13 million raised in Q1 and subsequent to Q1 is sufficient to fund operations through the planned Q3 2026 NDA submission given the $4.5 million quarterly cash burn.
• Debt Structure: Review the terms of the Senior Secured Convertible Promissory Notes (SSCP Notes), specifically the 12% interest rate, conversion features, and the $2.0 million cash covenant maintenance.
• Equity Dilution: Assess the impact of the January 2026 offering and the May 2026 offering on share count and the classification of warrants as liabilities vs. equity.
• Related Party Dependence: Confirm the status of the 4Life agreement, noting that exclusivity was converted to non-exclusive rights in April 2026 due to missed sales commitments.
• Internal Control Remediation: Monitor progress on remediation of material weaknesses in financial reporting controls.